Comparative study of naturally occurring Huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease

Human Molecular Genetics

Volumn 24, Issue 4, 2015, Pages 913-925

  Barbaro, Brett A ^a   Lukacsovich, Tamas ^a   Agrawal, Namita ^a,b   Burke, John ^a   Bornemann, Doug J ^a   Purcell, Judith M ^a   Worthge, Shane A ^a   Caricasole, Andrea ^c   Weiss, Andreas ^c   Song, Wan ^a   Morozova, Olga A ^d   Colby, David W ^d   Marsh, J Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF DELHI   (India)

^c IRBM Promidis   (Italy)

^d UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CALPAIN; HUNTINGTIN; PEPTIDE FRAGMENT; POLYGLUTAMINE; HTT PROTEIN, HUMAN; HUNTINGTIN PROTEIN, DROSOPHILA; MICROTUBULE ASSOCIATED PROTEIN; NERVE PROTEIN; PEPTIDE;

ARTICLE; CAG REPEAT; COMPARATIVE STUDY; CONTROLLED STUDY; DROSOPHILA; EXON; EXON 1; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RNA SPLICING; TRANSGENE; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; MALE; METABOLISM; NERVE CELL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEINOSIS; TRANSGENIC ANIMAL;

AMYLOID; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; EXONS; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS;

EID: 84922440152     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu504     Document Type: Article

References (50)

1. Gafni, J., Hermel, E., Young, J., Wellington, C., Hayden, M. and Ellerby, L. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem., 279, 20211-20220.
2. Lunkes, A., Lindenberg, K.S., Ben-Haiem, L., Weber, C., Devys, D., Landwehrmeyer, G.B., Mandel, J.L. and Trottier, Y. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell, 10, 259-269.
3. Ratovitski, T., Nakamura, M., D'Ambola, J., Chighladze, E., Liang, Y., Wang, W., Graham, R., Hayden, M., Borchelt, D., Hirschhorn, R. et al. (2007) N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle, 6, 2970-2981.
4. Wellington, C., Singaraja, R., Ellerby, L., Savill, J., Roy, S., Leavitt, B., Cattaneo, E., Hackam, A., Sharp, A., Thornberry, N. et al. (2000) Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem., 275, 19831-19838.
5. Wellington, C.L. and Hayden, M.R. (2000) Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genetics, 57, 1-10.
6. Sathasivam, K., Neueder, A., Gipson, T.A., Landles, C., Benjamin, A.C., Bondulich, M.K., Smith, D.L., Faull, R.L., Roos, R.A., Howland, D. et al. (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA, 110, 2366-2370.
7. Graham, R., Deng, Y., Slow, E., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 125, 1179-1191.
8. Bischof, J., Maeda, R.K., Hediger, M., Karch, F. and Basler, K. (2007) An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases. Proc. Natl Acad. Sci. USA, 104, 3312-3317.
9. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
10. Agrawal, N. (2005) Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. USA, 102, 3777-3781.
11. Steffan, J.S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L.C., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y.-Z., Cattaneo, E. et al. (2004) SUMO modification of huntingtin and Huntington's disease pathology. Science, 304, 100-104.
12. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M. et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413, 739-743.
13. Bennett, E.J., Shaler, T.A., Woodman, B., Ryu, K.-Y., Zaitseva, T.S., Becker, C.H., Bates, G.P., Schulman, H. and Kopito, R.R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature, 448, 704-708.
14. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
15. Mende-Mueller, L.M., Toneff, T., Hwang, S.R., Chesselet, M.F. and Hook, V.Y. (2001) Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N-and C-terminal HTT fragments in Huntington's disease striatum. J. Neurosci., 21, 1830-1837.
16. Gafni, J. and Ellerby, L.M. (2002) Calpain activation in Huntington's disease. J. Neurosci., 22, 4842-4849.
17. Kim, Y.J., Yi, Y., Sapp, E., Wang, Y., Cuiffo, B., Kegel, K.B., Qin, Z.H., Aronin, N. and DiFiglia, M. (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. USA, 98, 12784-12789.
18. Goldberg, Y.P., Nicholson, D.W., Rasper, D.M., Kalchman, M.A., Koide, H.B., Graham, R.K., Bromm, M., Kazemi-Esfarjani, P., Thornberry, N.A., Vaillancourt, J.P. et al. (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genetics, 13, 442-449.
19. Landles, C., Weiss, A., Franklin, S., Howland, D. and Bates, G. (2012) Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ 150 knock-in mouse model of Huntington's disease. PLoS Curr., 4, e4fd085bfc9973.
20. Weiss, K.R., Kimura, Y., Lee, W.-C.M. and Littleton, J.T. (2012) Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics, 190, 581-600.
21. Phelps, C.B. and Brand, A.H. (1998) Ectopic gene expression in Drosophila using GAL4 system. Methods, 14, 367-379.
22. Marsh, J.L. and Thompson, L.M. (2004) Can flies help humans treat neurodegenerative diseases? Bio Essays, 26, 485-496.
23. Marsh, J., Walker, H., Theisen, H., Zhu, Y.-Z., Fielder, T., Purcell, J. and Thompson, L. (2000) Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Gen., 9, 13-25.
24. Ossato, G., Digman, M.A., Aiken, C., Lukacsovich, T., Marsh, J.L. and Gratton, E. (2010) A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys. J., 98, 3078-3085.
25. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. and Glabe, C.G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
26. Sanchez, I., Mahlke, C. and Yuan, J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature, 421, 373-379.
27. Kazantsev, A.G. and Hersch, S.M. (2007) Drug targeting of dysregulated transcription in Huntington's disease. Prog. Neurobiol., 83, 249-259.
28. Slepko, N., Bhattacharyya, A.M., Jackson, G.R., Steffan, J.S., Marsh, J.L., Thompson, L.M. and Wetzel, R. (2006) Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proc. Natl Acad. Sci. USA, 103, 14367-14372.
29. Sinadinos, C., Burbidge-King, T., Soh, D., Thompson, L.M., Marsh, J.L., Wyttenbach, A. and Mudher, A.K. (2009) Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol. Dis., 34, 389-395.
30. Bolte, S. and Cordelieres, F.P. (2006) A guided tour into subcellular colocalization analysis in light microscopy. J. Microscopy, 224, 213-232.
31. Gupta, S., Jie, S. and Colby, D.W. (2012) Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay. J. Biol. Chem., 287, 9982-9989.
32. Baldo, B., Paganetti, P., Grueninger, S., Marcellin, D., Kaltenbach, L.S., Lo, D.C., Semmelroth, M., Zivanovic, A., Abramowski, D., Smith, D. et al. (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. Chem. Biol., 19, 264-275.
33. Gutekunst, C.A., Li, S.H., Yi, H., Mulroy, J.S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R.J., Hersch, S.M. and Li, X.J. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci., 19, 2522-2534.
34. Landles, C., Sathasivam, K., Weiss, A., Woodman, B., Moffitt, H., Finkbeiner, S., Sun, B., Gafni, J., Ellerby, L.M., Trottier, Y. et al. (2010) Proteolysis of mutant Huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem., 285, 8808-8823.
35. Schilling, G., Becher, M., Sharp, A., Jinnah, H., Duan, K., Kotzuk, J., Slunt, H., Ratovitski, T., Cooper, J., Jenkins, N. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genetics, 8, 397-407.
36. Tebbenkamp, A.T., Xu, G., Siemienski, Z.B., Janus, C., Fromholt, S.E., Brown, H.H., Swing, D., Tessarollo, L. and Borchelt, D.R. (2014) Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models. J. Huntingtons Dis., 3, 73-86.
37. Hughes, R., Lo, R., Davis, C., Strand, A., Neal, C., Olson, J. and Fields, S. (2001) Altered transcription in yeast expressing expanded polyglutamine. Proc. Natl Acad. Sci. USA, 98, 13201-13206.
38. Morley, J., Brignull, H., Weyers, J. and Morimoto, R. (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA, 99, 10417-10422.
39. Satyal, S., Schmidt, E., Kitagawa, K., Sondheimer, N., Lindquist, S., Kramer, J. and Morimoto, R. (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA, 97, 5750-5755.
40. Seredenina, T. and Luthi-Carter, R. (2012) What have we learned from gene expression profiles in Huntington's disease? Neurobiol. Dis., 45, 83-98.
41. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.-H.J. et al. (2007) Mutant Huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet., 16, 1845-1861.
42. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
43. Schilling, G., Klevytska, A., Tebbenkamp, A.T.N., Juenemann, K., Cooper, J., Gonzales, V., Slunt, H., Poirer, M., Ross, C.A. and Borchelt, D.R. (2007) Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J. Neuropathol. Exp. Neurol., 66, 313-320.
44. Trottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E.C. and Mandel, J.L. (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet., 10, 104-110.
45. Lunkes, A.A. and Mandel, J.L.J. (1998) A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet., 7, 1355-1361.
46. Pingoud, A. (2001) Structure and function of type II restriction endonucleases. Nucl. Acids Res., 29, 3705-3727.
47. Szybalski, W., Kim, S.C., Hasan, N. and Podhajska, A.J. (1991) Class-IIS restriction enzymes-a review. Gene, 100, 13-26.
48. Song, W., Smith, M.R., Syed, A., Lukacsovich, T., Barbaro, B.A., Purcell, J., Bornemann, D.J., Burke, J. and Marsh, J.L. (2013) Morphometric analysis of Huntington's disease neurodegeneration in Drosophila. Methods Mol. Biol., 1017, 41-57.
49. Bolte, S. and Cordelières, F.P. (2006) A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc., 224, 213-232.
50. Hamilton, M.A., Russo, R.C. and Thurston, R.V. (1977) Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ. Sci. Technol., 11, 714-719.